




Figure 1.




Figure 2.




Figure 3.




Figure 4.



Adenovirus is superior to vaccinia in inducing cellular anti-tumor immunity; a critical feature for enhancing adoptive cell therapy




Figure 5.




Figure 6.



BiTE delivered by oncolytic adenovirus targets all classes of T-cells against tumors, including anti-viral T-cells (which are generally considered counterproductive for tumor therapy)




Figure 7.




Figure 8.




Figure 9.




Figure 10.




Figure 11.




Figure 12.




Figure 13A.




Figure 13B.




Figure 14.




Figure 15.




Figure 16.




Figure 17.




Figure 18.




Figure 19.




Figure 20.




Figure 21.